Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination Setty M.
Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination Setty M. Maga?a, BS; B.
Medications Nerve pain is hard to treat. Treatment usually helps but often does not relieve all of your pain
BACKGROUND: Findings from a small clinical study suggested that statins may counteract the therapeutic effects of interferon beta (IFNbeta) in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: We conducted a post hoc analysis of data from the Safety and Efficacy of Natalizumab in Combination With IFNbeta-1a in Patients With Relapsing-Remitting Multiple Sclerosis (SENTINEL) study to determine the effects of statins on efficacy of IFNbeta. SENTINEL was a prospective trial of patients with RRMS treated with natalizumab (Tysabri, Biogen Idec, Inc., Cambridge, MA) plus IM IFNbeta-1a (Avonex, Biogen Idec, Inc.) 30 microg compared with placebo plus IM IFNbeta-1a 30 microg.
BACKGROUND: Anti-aquaporin-4 antibodies are believed to have a central pathogenetic role in neuromyelitis optica (NMO). B-cell activating factor (BAFF) is one of the crucial factors that determines the fate and survival of B cells and may play a role in induction of antibody-mediated autoimmunity. OBJECTIVES: To evaluate the blood and cerebrospinal fluid (CSF) levels of BAFF in NMO and multiple sclerosis (MS) patients
Background: Neuromyelitis optica (NMO) is characterized by severe optic neuritis and transverse myelitis. A disease-specific autoantibody against aquaporin (AQP) 4, mainly expressed in astrocytic foot processes, was found in the sera from patients with NMO.
Background: Neuromyelitis optica (NMO) is a severe demyelinating disease often leading to serious disability. Accumulating evidence now implicates humoral mechanisms in its pathogenesis.
Background: Using an anti-aquaporin-4 (AQP4) antibody assay discovered in 2005, Japanese patients with neuromyelitis optica (NMO) can easily be differentially diagnosed from those with opticospinal multiple sclerosis (MS).
Background: There are limited number of studies investigating efficacy and safety of plasma exchange (PLEX) in treating acute demyelinating diseases like Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO). In a randomised double-blind trial of PLEX in treating acute demyelinating attacks,42% of patients on active treatment had significant improvement compared to 5.9% on sham.